The expiration of patent protection and the subsequent sharp decline in sales have become a crucial topic for many pharmaceutical companies in recent years. The effort invested in designing strategies to cushion the adverse effects of patent expiry has increased considerably. One strategy, the launch of a second brand with a lower price, is frequently discussed as a potentially promising new option but has rarely been implemented. This contribution focuses on this fighter-brand strategy, its strengths and weaknesses and compares it to other pricing strategies. Moreover, it provides a detailed analysis of a major case example where a fighter brand was launched, the patent expiry of Zocor in Germany.
Get full access to this article
View all access options for this article.
References
1.
RaaschA.-C. (2006). Der Patentauslauf von Pharmazeutika als Herausforderung beim Management des Produktlebenszyklus, DUV, Wiesbaden.
2.
JamesB. (1982). The Marketing of Generic Drugs — A Guide to Counter-Strategies for the Technology Intensive Pharmaceutical Companies, Associated Business Press, London.
3.
AgrawalM.ThakkarN. (1997). Surviving patent expiration: Strategies for marketing pharmaceutical products. J. Prod. Brand Manage. 6(5). 305–314.
4.
ChandonP. (2004). Innovative marketing strategies after patent expiry: The case of GSK's antibiotic Clamoxyl in France. J. Med. Market. 4(1). 65–73.
5.
KearneyAT (1998). Patent Expiry and the Battle Against Generics — Strategies for Protecting Market Share and Profits, Chicago.
6.
MestreFerrándiz J. (1999). The impact of generic goods in the pharmaceutical industry. Health Econ.8, 599–612.
7.
BerndtE.KyleM.LingD. (2003). The long shadow of patent expiration — Generic entry and Rx-to-OTC switches in FeenstraR.ShapiroM. (eds.), Scanner Data and Price Indexes, National Bureau of Economic Research, Chicago, pp. 229–267.
8.
BarakA.WilsonG. (2003). Pricing policies to handle patent loss or expiry. J. Med. Market. 3(3). 245–249.
9.
LiangB. (1996). The anticompetitive nature of brandname firm introduction of generics before patent expiration. Antitrust Bull. 41(3), 599–635.
